STOCK TITAN

ARROWHEAD PHARMACEUTICALS (ARWR) SEC Filings, Apr-May 2026

ARWR NASDAQ
Form 144
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.47%
Tags
other
-
Rhea-AI Summary

Arrowhead Pharmaceuticals, Inc. reported a sharp swing to a loss for the quarter ended March 31, 2026. Revenue was $73.7 million, down from $542.7 million a year earlier, when it booked large milestone payments, leading to a net loss attributable to Arrowhead of $132.7 million versus net income of $370.4 million in the prior-year quarter.

For the first six months, revenue totaled $337.8 million and the net loss was $101.9 million. Cash, cash equivalents and restricted cash were $188.5 million, with available-for-sale securities of $1.60 billion, supporting ongoing R&D spending of $350.5 million over six months and a growing collaboration portfolio with Sarepta, Novartis and Sanofi.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.75%
Tags
quarterly report
-
Rhea-AI Summary

Arrowhead Pharmaceuticals reported fiscal 2026 second quarter revenue of $73.7 million, down sharply from $542.7 million a year earlier, leading to a net loss of $132.7 million or -$0.93 per diluted share versus net income of $370.4 million or $2.75 previously. Total cash resources rose to $1.78 billion as of March 31, 2026, supported by concurrent offerings of $700 million in 0.00% convertible senior notes due 2032 and a $230 million common equity issuance, plus a capped call to limit dilution.

The company highlighted growing commercial traction for REDEMPLO in familial chylomicronemia syndrome, with more than 400 prescriptions, about 180 patients shipped, and most use in patients new to the APOC3 class. Arrowhead also expanded REDEMPLO’s global regulatory footprint, advanced its RNAi pipeline in cardiometabolic disease and obesity, and signed a worldwide license with Madrigal Pharmaceuticals for ARO-PNPLA3, including a $25 million upfront payment and up to $975 million in potential milestones.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.75%
Tags
current report
Rhea-AI Summary

Arrowhead Pharmaceuticals filed a Schedule 13G reporting that FMR LLC beneficially owned 7,349,106.75 shares of common stock, representing 5.2% of the class as shown in the filing. The cover shows sole voting power of 7,323,647.12 and sole dispositive power of 7,349,106.75. The filing lists an Exhibit referencing a related 13d-1(k)(1) agreement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.62%
Tags
ownership
-
Rhea-AI Summary

Arrowhead Pharmaceuticals disclosure: Vanguard Capital Management reports beneficial ownership of 7,081,293 shares of Common Stock, representing 5.05% of the class. The filer reports sole voting power for 1,048,877 shares and sole dispositive power for 7,081,293 shares. The filing is signed on 04/29/2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.18%
Tags
ownership
-
Rhea-AI Summary

Arrowhead Pharmaceuticals Inc ownership disclosure: Vanguard Portfolio Management reports beneficial ownership of 7,269,957 shares of common stock, representing 5.19% of the class. The filing states Vanguard has sole dispositive power over these shares and sole voting power over 123,821 shares. The holdings include securities held for Vanguard funds and managed accounts.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.57%
Tags
ownership
Rhea-AI Summary

Arrowhead Pharmaceuticals’ Chief Financial Officer Daniel Joseph Apel sold 13,095 shares of common stock on April 22, 2026 in open-market transactions. The sales occurred at weighted average prices ranging from about $69.50 to $71.97 per share under a pre-established Rule 10b5-1 trading plan.

Following these sales, Apel directly holds 162,905 shares of Arrowhead common stock, which includes shares underlying previously reported restricted stock units that remain subject to vesting conditions. A portion of the disposition was made to satisfy tax withholding obligations related to equity compensation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.42%
Tags
insider
-
Rhea-AI Summary

Arrowhead Pharmaceuticals' Chief Medical Officer, James C. Hamilton, sold 10,000 shares of common stock in an open-market transaction at a weighted average price of $75.00 per share. The sale was made under a pre-arranged Rule 10b5-1 trading plan. Following this sale, Hamilton directly holds 226,958 shares, including shares underlying Restricted Stock Units, some of which remain subject to vesting conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.42%
Tags
insider
-
Rhea-AI Summary

Arrowhead Pharmaceuticals reports that BlackRock, Inc. beneficially owned 17,104,084 shares of Common Stock, representing 12.2% of the class as of 03/31/2026. The filing states BlackRock has sole voting power for 16,769,679 shares and sole dispositive power for 17,104,084 shares. The filing is an amendment (No. 5) to a Schedule 13G/A and is signed by a BlackRock managing director on 04/24/2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.42%
Tags
ownership
Rhea-AI Summary

Arrowhead Pharmaceuticals (ARWR) officer James Hamilton reported a proposed sale of 10,000 common shares, with an aggregate market value of $749,997.60 and an approximate sale date of April 23, 2026. Merrill Lynch is named as the broker. Hamilton's reported sales during the past three months included 10,000 common shares sold March 5, 2026, for gross proceeds of $641,870.05.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
other

FAQ

How many ARROWHEAD PHARMACEUTICALS (ARWR) SEC filings are available on StockTitan?

StockTitan tracks 79 SEC filings for ARROWHEAD PHARMACEUTICALS (ARWR), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for ARROWHEAD PHARMACEUTICALS (ARWR)?

The most recent SEC filing for ARROWHEAD PHARMACEUTICALS (ARWR) was filed on November 12, 2026.